stock-detail (KERX)

Oncology Corporate Profile

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
perifosine (+ bortezomib and dexamethasone) / KRX-0401AKT inhibitor1st line metastatic Multiple MyelomaIIIAEterna Zentaris
perifosine (+ capecitabine) / KRX-0401AKT inhibitor2nd line metastatic colorectal cancerIIIAEterna Zentaris
perifosine (+ radiotherapy) / KRX-0401AKT inhibitor1st line metastatic Non Small cell lung cancer (NSCLC)IIAEterna Zentaris
perifosine (+ trastuzumab) / KRX-0401AKT inhibitorBreast cancerIIAEterna Zentaris
perifosine / KRX-0401AKT inhibitorRenal cell carcinoma (RCC)IIAEterna Zentaris
perifosine (+ imatinib) / KRX-0401AKT inhibitorSarcomaIIAEterna Zentaris
perifosine / KRX-0401AKT inhibitorSarcomaIIAEterna Zentaris
perifosine / KRX-0401AKT inhibitorNon Small Cell Lung Cancer (NSCLC)IAEterna Zentaris
perifosine / KRX-0401AKT inhibitorVarious cancer typesIAEterna Zentaris

Recent News Headlines

Spectrum Pharmaceuticals Begins Enrolling Patients in Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer

1/29/2016 12:00 pm

(Yahoo! Finance) Jan 29, 2016 - The study is being conducted under Special Protocol Assessment (SPA) agreement with the FDA; this registrational, randomized, controlled Phase 3 study (ADVANCE) will evaluate SPI-2012 as a treatment for chemotherapy-induced neutropenia in approximately 580 patients with breast cancer.

Researchers Focus on Risk Factors for Leukemia After Breast Cancer Treatment

12/7/2015 02:02 pm

(U.S. News & World Report/HealthDay News) Dec 7, 2015 - Researchers say they're zeroing in on factors that may increase the risk of leukemia after breast cancer treatment.

Gene Pair Plays Crucial Role in Colon Cancer, Penn Vet Team Shows

12/7/2015 02:02 pm

(Penn News) Dec 3, 2015 - In a new study out this month in the journal Cell Reports, researchers from the University of Pennsylvania describe two related genes in the Musashi family that are required for colon cancer to develop, and that may be useful targets for effective treatment.

Alopexx Oncology Presents Encouraging Phase I/II Clinical Data On DI-Leu16-IL2 At The American Society Of Hematology Annual Meeting

12/7/2015 02:01 pm

(TheStreet) Dec 7, 2015 - Alopexx Oncology, LLC announced today data from an ongoing Phase I/II trial of DI-Leu16-IL2, a novel immunocytokine that is a fusion of an anti-CD20 antibody and the cytokine IL2, in patients with relapsed/refractory Non-Hodgkin lymphoma (NHL).

Epizyme Presents Updated Data from Ongoing Phase 1 Study of Tazemetostat Showing Objective, Durable Responses in Relapsed or Refractory Non-Hodgkin Lymphoma

12/7/2015 02:01 pm

(Epizyme) Dec 7, 2015 - Epizyme, Inc., a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, reported updated results from the ongoing phase 1 trial of tazemetostat (EPZ-6438), a first-in-class oral EZH2 inhibitor.

Acetylon Presents Data from Three Phase 1b Studies of Ricolinostat (ACY-1215) for the Treatment of Lymphoma and Multiple Myeloma

12/7/2015 02:01 pm

(Acetylon) Dec 7, 2015 – Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced results from three Phase 1b clinical trials of the selective HDAC6 inhibitor, ricolinostat (ACY-1215), in different single-agent and combination regimens for the treatment of lymphoma and multiple myeloma.

New Data at ASH 2015 from the Multiple Myeloma Research Foundation (MMRF) CoMMpass StudySM Show Significant Advances in the Understanding of Multiple Myeloma Genomics

12/7/2015 02:01 pm

(Yahoo! Finance [India]) Dec 7, 2015 – The Multiple Myeloma Research Foundation (MMRF) is presenting today new data from the MMRF CoMMpass StudySM – the most comprehensive long-term genomic study ever conducted in myeloma and one that may significantly advance the understanding of multiple myeloma.

Early Detection of Breast Cancer Backed by U.K. Study

12/7/2015 02:01 pm

(Wall Street Journal) Dec 4, 2015 - Diagnosing and treating milk-duct carcinoma lowers number of invasive cases found within three years, researchers say.

IMBRUVICA® (ibrutinib) Phase 3 RAY Data Show Significant Improvements in Progression-Free Survival Versus Temsirolimus in Patients with Relapsed or Refractory Mantle Cell Lymphoma

12/7/2015 02:00 pm

(Janssen) Dec 7, 2015 - Data from the Phase 3 RAY (MCL3001) study, an investigational clinical trial, showed oral IMBRUVICA® (ibrutinib) significantly improved progression-free survival (PFS; the primary endpoint) versus intravenous temsirolimus in patients with relapsed or refractory mantle cell lymphoma (MCL).

First Data Unveiled from CALLISTO Program Examining the Use of XARELTO® (rivaroxaban) for Treating Blood Clots in People with Cancer

12/7/2015 02:00 pm

(TheStreet) Dec 7, 2015 - Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the first results from CALLISTO, a comprehensive research program that includes nine studies of their non-vitamin K antagonist oral anticoagulant (NOAC) rivaroxaban in people with active cancer.

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data Presentations in Patients with Acute Myeloid Leukemia at ASH 2015

12/7/2015 02:00 pm

(Stockhouse) Dec 7, 2015 - 33A combination therapy and monotherapy demonstrate encouraging anti-leukemic activity in AML; data highlighted in oral presentations; planning 33a phase 3 trial in older AML patients.

Phase III Data Shows Sandoz' Proposed Biosimilar Pegfilgrastim Has Similar Safety And Efficacy As The Reference Product

12/7/2015 02:00 pm

(NASDAQ) Dec 7, 2015 - Sandoz, a Novartis company and global leader in biosimilars, today announced results from the PROTECT 2 study which compared the safety and efficacy of proposed biosimilar pegfilgrastim with the reference product, Neulasta®.

Amgen Presents Data From Three Trials Evaluating BLINCYTO® (blinatumomab) In Acute Lymphoblastic Leukemia At ASH 2015

12/7/2015 02:00 pm

(Amgen) Dec 7, 2015 - BLINCYTO, only Bispecific T Cell Engager (BITE®) immunotherapy approved in US and EU, shows benefit in phase 2 trial in patients with persistent or recurrent minimal residual disease (MRD); data show positive outcomes in difficult-to-treat patient subpopulations.

MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study

12/7/2015 02:00 pm

(TheStreet) Dec 7, 2015 - MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, today announced positive results from a Phase II study of its investigational drug candidate Pracinostat in combination with azacitidine (marketed as Vidaza®) in elderly patients with newly diagnosed acute myeloid leukemia (AML).

Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma (HL) Treatment Paradigm Through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ASH 2015

12/7/2015 02:00 pm

(Yahoo! Finance) Dec 7, 2015 - Seattle Genetics, Inc. today highlighted several data presentations at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015, evaluating ADCETRIS (brentuximab vedotin) as both monotherapy and combination therapy in multiple Hodgkin lymphoma (HL) disease settings.

New Clinical Data on MorphoSys's Blood Cancer Drug Candidate MOR208 in NHL and CLL Presented at ASH Annual Meeting

12/7/2015 02:00 pm

(MorphoSys AG) Dec 7, 2015 - MorphoSys AG today announced clinical data on its proprietary drug candidate MOR208. MOR208 is a potent anti-CD19 antibody with a proprietary modification to the Fc portion that is being developed to treat B cell malignancies.

The Horrific Destruction of Biotech Shareholder Value In One Simple Chart

6/28/2013 02:05 pm

(TheStreet) June 24, 2013 - Charts can sometimes tell a story much better than words, and so it is with the devastating shareholder tragedy otherwise known as Cell Therapeutics.

Keryx Finally Succeeds With a Clinical Trial, for Kidney Disease Drug

1/28/2013 12:05 pm

(Xconomy) Jan 28, 2013 - It looks like a Hail Mary pass came through for Keryx Biopharmaceuticals. In the past few years, both of New York-based Keryx’s top drug candidates failed key clinical trials, leaving the company to bet all its fortunes on its one remaining drug, meant for kidney dialysis patients.

Biotech Stock Mailbag: Keryx, Sangamo, Threshold and Amarin

1/25/2013 12:01 pm

(The Street) Jan 25, 2013 - The Biotech Stock Mailbag is open.

Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference

7/10/2012 12:03 pm

[PR Newswire] - NEW YORK, July 10, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 7th Annual JMP Securities ...

Merger and Acquisition Activity and Speculation Growing as Large Pharmaceuticals Look to Replace Revenues From Lost Patents

7/3/2012 12:02 pm

[Marketwire] - NEW YORK, NY-- - Despite the recent economic slowdown, the Biotech Industry has been home to some of the strongest performers in the market in 2012. The SPDR S&P Biotech ETF and the First Trust NYSE Arca ...